Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05CVC
|
|||
| Former ID |
DIB004951
|
|||
| Drug Name |
90Y-cG250
|
|||
| Synonyms |
Radiolabeled G250 derived mAb (cancer), Wilex/Ludwig Institute; 90Y-DOTA-cG250
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1] | |
| Company |
Wilex AG
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Carbonic anhydrase IX (CA-IX) | Target Info | . | [2] |
| KEGG Pathway | Nitrogen metabolism | |||
| Pathway Interaction Database | HIF-1-alpha transcription factor network | |||
| Reactome | Regulation of gene expression by Hypoxia-inducible Factor | |||
| Reversible hydration of carbon dioxide | ||||
| WikiPathways | Vitamin D Receptor Pathway | |||
| Reversible Hydration of Carbon Dioxide | ||||
| Regulation of Hypoxia-inducible Factor (HIF) by Oxygen | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00199875) Treatment of Patients With Advanced Renal Cancer With a Radio-labeled Antibody, Yttrium-90 Conjugated Chimeric G250. U.S. National Institutes of Health. | |||
| REF 2 | Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma. Int J Mol Sci. 2013 May 29;14(6):11402-23. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.